DK552285A - Proteinkonjugat - Google Patents

Proteinkonjugat Download PDF

Info

Publication number
DK552285A
DK552285A DK552285A DK552285A DK552285A DK 552285 A DK552285 A DK 552285A DK 552285 A DK552285 A DK 552285A DK 552285 A DK552285 A DK 552285A DK 552285 A DK552285 A DK 552285A
Authority
DK
Denmark
Prior art keywords
protein
Prior art date
Application number
DK552285A
Other languages
Danish (da)
English (en)
Other versions
DK552285D0 (da
Inventor
Andrew John Garman
Original Assignee
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10570497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK552285(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beecham Group Plc filed Critical Beecham Group Plc
Publication of DK552285D0 publication Critical patent/DK552285D0/da
Publication of DK552285A publication Critical patent/DK552285A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK552285A 1984-11-30 1985-11-28 Proteinkonjugat DK552285A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848430252A GB8430252D0 (en) 1984-11-30 1984-11-30 Compounds

Publications (2)

Publication Number Publication Date
DK552285D0 DK552285D0 (da) 1985-11-28
DK552285A true DK552285A (da) 1986-05-31

Family

ID=10570497

Family Applications (1)

Application Number Title Priority Date Filing Date
DK552285A DK552285A (da) 1984-11-30 1985-11-28 Proteinkonjugat

Country Status (9)

Country Link
US (1) US4935465A (OSRAM)
EP (1) EP0183503B1 (OSRAM)
JP (2) JPH0717517B2 (OSRAM)
AU (1) AU5044585A (OSRAM)
DE (1) DE3586313T2 (OSRAM)
DK (1) DK552285A (OSRAM)
GB (1) GB8430252D0 (OSRAM)
GR (1) GR852877B (OSRAM)
PT (1) PT81581B (OSRAM)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4842868A (en) * 1986-09-26 1989-06-27 Helwing Robert F Covalently bonded active agents with carbonium ion base groups
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
IE64284B1 (en) * 1987-08-03 1995-07-26 Ddi Pharmaceuticals Conjugates of superoxide dismutase
CA1308377C (en) * 1987-08-21 1992-10-06 Henry Berger, Jr. Complex of polyethyleneglycol and tissue plasminogen activator
JPH079429B2 (ja) * 1988-10-12 1995-02-01 財団法人化学及血清療法研究所 人工担体およびその製造方法
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5565519A (en) * 1988-11-21 1996-10-15 Collagen Corporation Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
EP0395918A3 (en) * 1989-04-13 1991-10-23 Vascular Laboratory, Inc. Plasminogen activator complex of pure pro-urokinase covalently bound by a disulfide bridge to human serum albumin
AU651949B2 (en) * 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US5767072A (en) * 1989-09-14 1998-06-16 Board Of Regents, The University Of Texas System Therapeutic compositions comprising a CD4 peptide and methods of treatment of HIV infections
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
AU5610194A (en) 1992-11-16 1994-06-08 Centocor Inc. Compounds having reduced immunogenicity and a method of reducing the immunogenicity of compounds
AU5743994A (en) * 1992-12-10 1994-07-04 Enzon, Inc. Glycolipid enzyme-polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
PT730470E (pt) * 1993-11-10 2002-08-30 Enzon Inc Conjugados melhorados de interferao-polimero
US6458762B1 (en) 1994-03-28 2002-10-01 Baxter International, Inc. Therapeutic use of hemoglobin for preserving tissue viability and reducing restenosis
WO1996004340A1 (en) * 1994-08-04 1996-02-15 Gordon George Wallace Conducting electroactive biomaterials
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
JPH10510516A (ja) * 1994-12-07 1998-10-13 ノボ ノルディスク アクティーゼルスカブ アレルゲン性を減らしたポリペプチド
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US6428790B1 (en) * 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6458889B1 (en) 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US7883693B2 (en) * 1995-12-18 2011-02-08 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
PT1704878E (pt) 1995-12-18 2013-07-17 Angiodevice Internat Gmbh Composições de polímeros reticulados e métodos para a sua utilização
US6833408B2 (en) * 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
WO1997024421A2 (en) * 1995-12-29 1997-07-10 The Procter & Gamble Company Detergent compositions comprising immobilized enzymes
JP2000506119A (ja) * 1996-02-15 2000-05-23 ノボ ノルディスク アクティーゼルスカブ ポリペプチドのコンジュゲーション
US6106828A (en) * 1996-02-15 2000-08-22 Novo Nordisk A/S Conjugation of polypeptides
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
JP2001503396A (ja) * 1996-10-11 2001-03-13 アルザ コーポレイション 治療用リポソーム組成物および方法
US6416756B1 (en) 1997-01-10 2002-07-09 Novozymes A/S Modified protease having 5 to 13 covalently coupled polymeric molecules for skin care
JPH10276776A (ja) * 1997-04-07 1998-10-20 Toyobo Co Ltd 可逆的に不活化された耐熱性ｄｎａポリメラーゼ
AU3977499A (en) 1998-05-08 1999-11-29 University Of Southern California Size enhanced fibrinolytic enzymes
CN1170543C (zh) * 1998-06-08 2004-10-13 弗·哈夫曼-拉罗切有限公司 PEG-IFN-α和三唑核苷在治疗慢性丙型肝炎中的用途
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
TWI242000B (en) * 1998-12-10 2005-10-21 Univ Southern California Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
IL146055A0 (en) 1999-04-23 2002-07-25 Alza Corp Conjugate having a cleavable linkage for use in a liposome
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
WO2001004287A1 (en) * 1999-07-07 2001-01-18 Maxygen Aps A method for preparing modified polypeptides
US6423666B1 (en) 1999-10-05 2002-07-23 Bio-Rad Laboratories, Inc. Large-pore chromatographic beads prepared by suspension polymerization
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
EP2133098A1 (en) 2000-01-10 2009-12-16 Maxygen Holdings Ltd G-CSF conjugates
PL206148B1 (pl) 2000-02-11 2010-07-30 Bayer HealthCare LLCBayer HealthCare LLC Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
US7829074B2 (en) * 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
WO2002074806A2 (en) 2001-02-27 2002-09-26 Maxygen Aps New interferon beta-like molecules
GB0123232D0 (en) * 2001-09-26 2001-11-21 Smith & Nephew Polymers
JP2005508162A (ja) * 2001-10-02 2005-03-31 ジェネンテック・インコーポレーテッド Ａｐｏ−２リガンド変異体とその使用法
ATE503498T1 (de) 2002-06-21 2011-04-15 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
EP1556076A4 (en) 2002-06-24 2009-07-08 Genentech Inc APO-2 LIGAND / TRAIL VARIANTS AND ITS USES
WO2004043396A2 (en) * 2002-11-09 2004-05-27 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
EP1583561A3 (en) * 2002-12-30 2005-12-07 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
JP2006516548A (ja) * 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
US20040151766A1 (en) * 2003-01-30 2004-08-05 Monahan Sean D. Protein and peptide delivery to mammalian cells in vitro
GB0305989D0 (en) * 2003-03-15 2003-04-23 Delta Biotechnology Ltd Agent
EP2263684A1 (en) 2003-10-10 2010-12-22 Novo Nordisk A/S IL-21 derivatives
EP2633866A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US20100028995A1 (en) * 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
US20050265925A1 (en) * 2004-04-21 2005-12-01 Samuel Zalipsky Releasable linkage and compositions containing same
KR100974733B1 (ko) 2004-04-28 2010-08-06 안지오디바이스 인터내셔널 게엠베하 가교된 생합성물질을 형성하기 위한 조성물 및 시스템, 및이와 관련된 제조 및 사용 방법
MXPA06014684A (es) 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
WO2006091231A2 (en) 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
WO2006034128A2 (en) 2004-09-17 2006-03-30 Angiotech Biomaterials Corporation Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use
ATE542920T1 (de) 2004-12-22 2012-02-15 Ambrx Inc Modifiziertes menschliches wachstumshormon
US20060188498A1 (en) 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
EP2360170A3 (en) 2005-06-17 2012-03-28 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine
EP2339014B1 (en) 2005-11-16 2015-05-27 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
RU2008145084A (ru) 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
CA2663083A1 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
US8486384B2 (en) 2006-10-27 2013-07-16 University Of Southern California Lipidized interferon and methods of treating viral hepatitis
ES2385114T3 (es) 2007-03-30 2012-07-18 Ambrx, Inc. Polipéptidos de FGF-21 modificados y sus usos
JP2010538655A (ja) * 2007-09-12 2010-12-16 アナフォア インコーポレイテッド 自己免疫疾患についてのｈｓｐ７０に基づく治療
CA2702945C (en) 2007-10-23 2016-08-23 Nektar Therapeutics Al, Corporation Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom
CN101918439A (zh) * 2007-11-09 2010-12-15 阿纳福公司 用于治疗疾病的甘露糖结合凝集素融合蛋白
KR101656107B1 (ko) 2007-11-20 2016-09-08 암브룩스, 인코포레이티드 변형된 인슐린 폴리펩티드 및 이의 용도
MX2010008632A (es) 2008-02-08 2010-08-30 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
EP2318029B1 (en) 2008-07-23 2017-11-01 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
EP2342223B1 (en) 2008-09-26 2017-04-26 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
NZ592249A (en) 2008-09-26 2013-03-28 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines
JP2012504969A (ja) 2008-10-10 2012-03-01 アナフォア インコーポレイテッド Ｔｒａｉｌ−ｒ１及びｔｒａｉｌ−ｒ２に結合するポリペプチド
US20110318322A1 (en) * 2009-01-12 2011-12-29 Nektar Therapeutics Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer
WO2011043835A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that bind il-23r
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
SG181769A1 (en) 2009-12-21 2012-07-30 Ambrx Inc Modified porcine somatotropin polypeptides and their uses
WO2011107591A1 (en) 2010-03-05 2011-09-09 Rigshospitalet Chimeric inhibitor molecules of complement activation
WO2011143274A1 (en) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
EP3572091B1 (en) 2010-08-17 2023-12-13 Ambrx, Inc. Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
CA2834776A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
CN103930440A (zh) 2011-07-01 2014-07-16 拜耳知识产权有限责任公司 松弛素融合多肽及其用途
GB201117428D0 (en) * 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
EP2606884A1 (en) 2011-12-21 2013-06-26 Ecole Polytechnique Fédérale de Lausanne (EPFL) Inhibitors of notch signaling pathway and use thereof in treatment of cancers
CA2875989A1 (en) 2012-06-08 2013-12-12 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9732161B2 (en) 2012-06-26 2017-08-15 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
US9682934B2 (en) 2012-08-31 2017-06-20 Sutro Biopharma, Inc. Modified amino acids
EP3019522B1 (en) 2013-07-10 2017-12-13 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
MX2016014160A (es) 2014-05-01 2017-02-16 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos.
SG11201702824UA (en) 2014-10-24 2017-05-30 Bristol Myers Squibb Co Modified fgf-21 polypeptides and uses thereof
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
WO2018004338A1 (en) 2016-06-27 2018-01-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
WO2018148419A1 (en) 2017-02-08 2018-08-16 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
AU2019289917B2 (en) 2018-06-21 2025-01-09 Cellestia Biotech Ag Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts
LT3849614T (lt) 2018-09-11 2024-03-25 Ambrx, Inc. Interleukino-2 polipeptido konjugatai ir jų panaudojimas
AU2019361206A1 (en) 2018-10-19 2021-06-03 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
CA3128081A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
MA55596A (fr) 2019-04-10 2022-02-16 Cellestia Biotech Ag Inhibiteurs de la voie de signalisation notch et leur utilisation dans le traitement de cancers
KR20220151202A (ko) 2020-03-11 2022-11-14 암브룩스, 인코포레이티드 인터류킨-2 폴리펩타이드 접합체 및 그의 사용 방법
KR20220157445A (ko) 2020-03-24 2022-11-29 제넨테크, 인크. Tie2-결합제 및 사용방법
KR20230073200A (ko) 2020-08-20 2023-05-25 암브룩스, 인코포레이티드 항체-tlr 작용제 접합체, 그 방법 및 용도
EP4255409A1 (en) 2020-12-07 2023-10-11 Cellestia Biotech AG Pharmaceutical combinations for treating cancer
EP4008324A1 (en) 2020-12-07 2022-06-08 Cellestia Biotech AG Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
CN112451681B (zh) * 2020-12-09 2023-08-25 苏州大学 酸敏感型聚合物-药物偶联物及其制备和应用
AU2022249223A1 (en) 2021-04-03 2023-10-12 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof
EP4346816A2 (en) 2021-06-02 2024-04-10 Cellestia Biotech AG Compounds for use in a method for treating an autoimmune and inflammatory disease
EP4429661A1 (en) 2021-11-08 2024-09-18 Cellestia Biotech AG Pharmaceutical combinations for treating cancer
EP4223292A1 (en) 2022-02-07 2023-08-09 Cellestia Biotech AG Pharmaceutical combinations for treating cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3499007A (en) * 1964-12-05 1970-03-03 Cassella Farbwerke Mainkur Ag Addition products of maleic anhydride to polyalkylene ethers
GB1390716A (en) * 1972-06-27 1975-04-16 Mitsubishi Electric Corp Ester of trimellitic anhydride and process for producing the same
GB1479268A (en) * 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0038154B1 (en) * 1980-04-15 1983-09-21 Beecham Group Plc Allergens modified with polysarcosines
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
JPS5959629A (ja) * 1982-09-27 1984-04-05 Nippon Chem Res Kk 効力持続性組成物
JPS58225025A (ja) * 1982-06-24 1983-12-27 Nippon Chem Res Kk 効力持続性組成物
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4764368A (en) * 1984-08-29 1988-08-16 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4863735A (en) * 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
US4859736A (en) * 1987-03-30 1989-08-22 Ciba-Geigy Corporation Synthetic polystyrene resin and its use in solid phase peptide synthesis

Also Published As

Publication number Publication date
JPH0717517B2 (ja) 1995-03-01
JPH06279318A (ja) 1994-10-04
US4935465A (en) 1990-06-19
DE3586313T2 (de) 1993-01-21
JP2545339B2 (ja) 1996-10-16
PT81581A (en) 1985-12-01
EP0183503B1 (en) 1992-07-08
EP0183503A3 (en) 1988-01-07
DE3586313D1 (de) 1992-08-13
DK552285D0 (da) 1985-11-28
JPS61155333A (ja) 1986-07-15
GB8430252D0 (en) 1985-01-09
GR852877B (OSRAM) 1986-03-31
AU5044585A (en) 1986-07-17
PT81581B (en) 1987-07-22
EP0183503A2 (en) 1986-06-04

Similar Documents

Publication Publication Date Title
DK552285A (da) Proteinkonjugat
AT380762B (de) Hoergeraet
DK147385A (da) Klaebemiddel
AT379929B (de) Hoergeraet
DK184485D0 (da) Mejetaersker
DK606485A (da) Proteinhydrolysat
DK396084D0 (da) Klaebemiddel
DK600586D0 (da) Protein
ATA98284A (de) Schalplatte
AT386724B (de) Haecksler
ATA135485A (de) Maishaecksler
ATA237384A (de) Maehwerk
ATE36715T1 (de) 7-d-mandelamido-3-(1-sulfomethyltetrazol-5us840229
ATA45484A (de) Kimme
DK51585D0 (da) Proteinkoncentrater
AT389296B (de) Elektrokoagulator
AR231237A1 (es) Calzado-patin
BR8401156A (pt) Auto-balsa
BR6401644U (pt) Aduela balanco
ATA406084A (de) Schipasshalter
BR6401110U (pt) Espelho-tomadas
BR6400601U (pt) Fotocheque
BR6400113U (pt) Aquafolio
BR8401157A (pt) Auto-balsa
BR6400397U (pt) Isqueiro-cinzeiro

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment